Clinical Trial Update: A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the effect of GS-5737 on mucociliary clearance in healthy subjects; the trial sponsored by Gilead Sciences has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Cystic Fibrosis

Drugs mentioned

• GS-5737

Snippet

Sponsor: Gilead Sciences | Conditions: Cystic Fibrosis, Chronic Obstructive Pulmonary Disease | Phase 1 | Status: TERMINATED